How do you approach management of GLP-1 receptor agonist therapy in patients who develop NAION?

Short answer is I recommend stopping the GLP-1 agonist if one eye has already developed NAION, for the sake of protecting the fellow eye.

The fact is, our knowledge is still growing in this matter. While some studies indicate links between GLP-1 agonists and NAION, there are so many discussions around that. AAO and NANOS have provided some guidance on this. I think if a patient develops NAION in one eye, as there is a 20-30% chance for involvement of the other eye, every effort is valuable to re...

Great discussion. I think we are still far from a clear understanding of this topic. Much larger prospective studies are needed to provide more accurate guidance.